List of Studies ( Metabolite:HBMP 18:0_18:1_18:1)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004385 | AN007327 | Inducible deletion of DGAT1 and 2 from microglia exacerbates neurodegeneration and endolysosomal lipid accumulation in male PS19 mice | Brain | Mouse | Neurodegenerative disease | Denali Therapeutics | LC-MS |
| ST004205 | AN006993 | Lipidomic/Metabolomic Characterization of GPR34 KO, WT, TREM2 KO, and GPR34/TREM2 dKO iPSC1-derived microglia | Glial cells | Human | Neurodegenerative disease | Denali Therapeutics | LC-MS |
| ST004163 | AN006909 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Metabolic disease | Denali Therapeutics | LC-MS |
| ST004163 | AN006909 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST004059 | AN006715 | Targeted Lipid and Metabolite Profiling in Brains of ATP13A2 Knockout Mice | Brain | Mouse | Neurodegenerative disease | Denali Therapeutics | LC-MS |
| ST004059 | AN006715 | Targeted Lipid and Metabolite Profiling in Brains of ATP13A2 Knockout Mice | Brain | Mouse | Parkinsons disease | Denali Therapeutics | LC-MS |
